Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
Condition(s):Covid19; SARS (Severe Acute Respiratory Syndrome)Last Updated:March 4, 2022Withdrawn
Hide Studies Not Open or Pending
Condition(s):Covid19; SARS (Severe Acute Respiratory Syndrome)Last Updated:March 4, 2022Withdrawn
Condition(s):Covid19; SARS (Severe Acute Respiratory Syndrome)Last Updated:June 24, 2021Completed
Condition(s):Neoadjuvant Therapy \High Risk Prostate CancerLast Updated:October 13, 2021Unknown status
Condition(s):Metastatic Breast CancerLast Updated:September 24, 2021Completed
Condition(s):Covid19; SARS-CoV InfectionLast Updated:March 4, 2022Withdrawn
Condition(s):COVID-19Last Updated:November 19, 2021Completed
Condition(s):Efficacy and SafetyLast Updated:January 2, 2024Completed
Condition(s):Covid19Last Updated:August 18, 2023Terminated
Condition(s):COVID-19; SARS-CoV2; Androgenetic Alopecia; Prostate Cancer; Benign Prostatic Hyperplasia; SARS (Severe Acute Respiratory Syndrome)Last Updated:December 10, 2021Completed
Condition(s):Metastatic Castrate Resistant Prostate Cancer (mCRPC)Last Updated:March 17, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.